Advertisement

GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway

  • Linlin Wang
  • Jing Liu
  • Jinguo Liu
  • Xiaoyan Chen
  • Meijia Chang
  • Jing Li
  • Jian ZhouEmail author
  • Chunxue BaiEmail author
  • Yuanlin SongEmail author
Original Article – Cancer Research
  • 102 Downloads

Abstract

Purpose

Non-small-cell lung cancer (NSCLC) is the most common form of lung cancer. Gefitinib is one of the most accepted therapies against NSCLC in those carrying EGFR mutations, but it is only effective in approximately 20% of patients with NSCLC. Thus, alternative therapeutic interventions are urgently needed to overcome gefitinib resistance. Glutaredoxin (GLRX) plays a key role in oxidative stress. However, whether GLRX inhibition could enhance gefitinib efficacy in the gefitinib-resistant NSCLC cells is unknown. In this study, we aimed to determine whether combined inhibition of GLRX could enhance growth-inhibitory effects of gefitinib in gefitinib-resistant NSCLC cells.

Methods

Real-time PCR and western blotting were used to examine the mRNA and protein levels of GLRX in gefitinib-sensitive PC9 and HCC827 and -resistant human lung adenocarcinoma PC9R, HCC827R, and H1975 cells. Cell Counting Kit-8, flow cytometry, JC-1 staining, and reactive oxygen species (ROS) assays were used to evaluate cell proliferation, cell cycle progression, mitochondrial membrane potential, and ROS generation, respectively. Mouse tumor xenografts were used to assess the effect of GLRX in vivo.

Results

We found that GLRX was upregulated in gefitinib-resistant PC9R, HCC827R, and H1975 cells. GLRX inhibition enhanced the effects of geftinib in gefitinib-resistant cell proliferation in vitro and in vivo and promoted apoptosis and cell cycle arrest via the EGFR/Forkhead Box M1 (FoxM1) signaling pathway, indicating that combined inhibition of GLRX could enhance growth-inhibitory effects of gefitinib in gefitinib-resistant NSCLC cells.

Conclusions

Our results suggest that GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells. Thus, GLRX may represent a therapeutic target for increasing the efficiency of gefitinib treatment.

Keywords

GLRX Non-small-cell lung cancer Gefitinib Drug resistance FoxM1 

Notes

Author contributions

Jian Zhou, Chunxue Bai, and Yuanlin Song conceived and designed the study. Linlin Wang, Jing Liu, Jinguo Liu, Xiaoyan Chen, Meijia Chang, and Jing Li performed the experiments and statistical analyses. Linlin Wang, Jing Liu, Jinguo Liu, and Xiaoyan Chen wrote the paper. All authors read and approved the final manuscript.

Funding

This work was supported by National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” (no. 2018ZX09201002-006), Natural Science Foundation of China (no. 81570028, 81770039, and 81400018), Zhongshan Hospital Clinical Research Foundation (no. 2016ZSLC05), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B00), the State Key Basic Research Program (973) project (2015CB553404), and Project of Natural Science Foundation of Shandong Province (ZR2016HL39).

Compliance with ethical standards

Conflict of interest

Authors have no financial, professional, or personal conflicts to disclose.

Ethical approval

Animal experiments were approved by the Research Ethics Committee of Zhongshan Hospital, Fudan University (Shanghai, China) and all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Informed consent

No human participants were used in this study.

References

  1. Boddupalli S, Mein JR, Lakkanna S, James DR (2012) Induction of phase 2 antioxidant enzymes by broccoli sulforaphane: perspectives in maintaining the antioxidant activity of vitamins a. C e Front Gene 3:7–7.  https://doi.org/10.3389/fgene.2012.00007 Google Scholar
  2. Chan K, Han X-D, Kan YW (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen Proceedings of the National Academy of Sciences 98:4611–4616Google Scholar
  3. Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J (2012) Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 10:28CrossRefGoogle Scholar
  4. Elzagallaai A, Garcia-Bournissen F, Finkelstein Y, Bend J, Rieder M, Koren G (2011) Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han-Chinese child with a positive HLA-B* 1502 and negative in vitro toxicity assays: evidence for different pathophysiological mechanisms. J Popul Ther Clin Pharmacol 18:e1–e9Google Scholar
  5. Ercan D et al (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov  https://doi.org/10.1158/2159-8290.cd-12-0103 Google Scholar
  6. Ewald JA, Wilkinson JC, Guyer CA, Staros JV (2003) Ligand-and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res 282:121–131CrossRefGoogle Scholar
  7. Feng F et al (2007) Role of epidermal growth factor receptor degradation in gemcitabine-mediated. Cytotox Oncogene 26:3431CrossRefGoogle Scholar
  8. Gallogly MM, Starke DW, Mieyal JJ (2009) Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid Redox Signal 11:1059–1081.  https://doi.org/10.1089/ars.2008.2291 CrossRefGoogle Scholar
  9. Gallogly MM et al (2010) Glutaredoxin regulates apoptosis in cardiomyocytes via NFκB targets Bcl-2 and Bcl-xL. Implic Cardiac Aging Antioxid Redox Signal 12:1339–1353.  https://doi.org/10.1089/ars.2009.2791 CrossRefGoogle Scholar
  10. Gladyshev VN et al (2001) Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. J Biol Chem 276:30374–30380CrossRefGoogle Scholar
  11. Holmgren A (1976) Hydrogen donor system for Escherichia coli ribonucleoside-diphosphate reductase dependent upon glutathione. Proc Natl Acad Sci USA 73:2275–2279CrossRefGoogle Scholar
  12. Holmgren A (1979) Glutathione-dependent synthesis of deoxyribonucleotides. Purification and characterization of glutaredoxin from Escherichia coli. J Biol Chem 254:3664–3671Google Scholar
  13. Kris MA (2002) Phase II trial of ZD1839 (” Iressa”) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). In: Proc Am Soc Clin Oncol, p 292aGoogle Scholar
  14. Le X-F, Pruefer F, Bast RC (2005) HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4:87–95CrossRefGoogle Scholar
  15. Liu X, Jann J, Xavier C, Wu H (2015) Glutaredoxin 1 (Grx1) protects human retinal pigment epithelial cells from oxidative damage by preventing AKT glutathionylation invest. Ophthalmol Vis Sci 56:2821–2832.  https://doi.org/10.1167/iovs.14-15876 CrossRefGoogle Scholar
  16. Lundberg M et al (2001) Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem 276:26269–26275CrossRefGoogle Scholar
  17. Ma Q (2013) Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol 53:401–426CrossRefGoogle Scholar
  18. Mollbrink A et al (2014) Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome. Int J Immunopathol Pharmacol 27:169–183CrossRefGoogle Scholar
  19. Nagy P, Arndt-Jovin DJ, Jovin TM (2003) Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 285:39–49CrossRefGoogle Scholar
  20. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269.  https://doi.org/10.1345/aph.1G387 CrossRefGoogle Scholar
  21. Nicholson R, Gee J, Harper M (2001) EGFR and cancer prognosis. Eur J Cancer 37:9–15CrossRefGoogle Scholar
  22. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774.  https://doi.org/10.1038/nrc2947 CrossRefGoogle Scholar
  23. Park HJ et al (2009) FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28:2908–2918.  https://doi.org/10.1038/emboj.2009.239 CrossRefGoogle Scholar
  24. Raychaudhuri P, Park HJ (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71:4329–4333CrossRefGoogle Scholar
  25. Rho JK et al (2009) The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 7:1736–1743.  https://doi.org/10.1158/1541-7786.MCR-08-0504 CrossRefGoogle Scholar
  26. Rodriguez-Rocha H, Garcia Garcia A, Zavala-Flores L, Li S, Madayiputhiya N, Franco R (2012) Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson’s disease. Antioxid Redox Signal 17:1676–1693.  https://doi.org/10.1089/ars.2011.4474 CrossRefGoogle Scholar
  27. Sun H et al (2011) FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria. Cancer Lett 306:214–222CrossRefGoogle Scholar
  28. Tan X, Thapa N, Sun Y, Anderson RA (2015) A kinase-independent role for EGF receptor in autophagy. Initiat Cell 160:145–160CrossRefGoogle Scholar
  29. Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204CrossRefGoogle Scholar
  30. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754Google Scholar
  31. Wang L et al (2018) An acquired vulnerability of drug-resistant melanoma with therapeutic potential cell  https://doi.org/10.1016/j.cell.2018.04.012
  32. Weihua Z, Tsan R, Huang W-C, Wu Q, Chiu C-H, Fidler IJ, Hung M-C (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13:385–393CrossRefGoogle Scholar
  33. Xu N et al (2012) FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells. Acta Pharmacol Sin 33:675CrossRefGoogle Scholar
  34. Yamanaka S et al (2008) siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology 75:2–8CrossRefGoogle Scholar
  35. Yang F, Yi M, Liu Y, Wang Q, Hu Y, Deng H (2018) Glutaredoxin-1 silencing induces cell senescence via p53/p21/p16 signaling axis. J Proteome Res 17:1091–1100.  https://doi.org/10.1021/acs.jproteome.7b00761 CrossRefGoogle Scholar
  36. Yewale C, Baradia D, Vhora I, Patil S, Misra A (2013) Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34:8690–8707.  https://doi.org/10.1016/j.biomaterials.2013.07.100 CrossRefGoogle Scholar
  37. Yu J et al (2011) Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 17:1924–1934CrossRefGoogle Scholar
  38. Zhang F et al (2018) FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. Int J Cancer.  https://doi.org/10.1002/ijc.31278 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pulmonary Medicine, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Department of Pathology, The Affiliated Yantai Yuhuangding HospitalQingdao UniversityYantaiChina
  3. 3.Shanghai Respiratory Research InstituteShanghaiChina

Personalised recommendations